Targeting a single AML-associated antigen could lead to an antigen-negative relapse similar to the CD19-negative relapses (CD—cluster of differentiation) during B-cell acute lymphoblastic leukemia treatment with CD19 targeting [1]. Here, CD19 is linked to acute myeloid leukemia.